Royalty Pharma Expands Asia Push with Morgan Stanley Banker as Head of Region

Event summary

  • Royalty Pharma appoints Kenneth Sun as Senior Vice President and Head of Asia, effective May 2026.
  • Sun joins from Morgan Stanley, where he was Head of Asia Pacific Healthcare Investment Banking.
  • Asia-based biotech out-licensing deals reached $130 billion in 2025, up from $14 billion in 2021.
  • Royalty Pharma aims to establish a royalty market in Asia, mirroring its role in the Western biopharma sector.
  • Sun brings 18 years of investment banking experience, with a focus on Greater China healthcare transactions.

The big picture

Royalty Pharma's appointment of Kenneth Sun underscores the growing importance of Asia's biotech sector, where out-licensing deals have surged. The company aims to replicate its Western success by establishing a royalty market in Asia, leveraging Sun's extensive experience in healthcare investment banking. This move comes as multinational pharmaceutical companies increasingly recognize the value of Asian innovation, creating a new market opportunity for royalty-based funding.

What we're watching

Market Expansion
How Royalty Pharma's Asia push will affect its global royalty portfolio growth.
Execution Risk
Whether Sun can replicate his success in Western markets within Asia's diverse biotech landscape.
Deal Flow
The pace at which Royalty Pharma can secure significant royalty deals in Asia.